Health Care [ 2/12 ] | Biotechnology [ 22/74 ]
NASDAQ | Common Stock
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.
In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.
The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 26 | 5.82 Decreased by -12.21% | 7.44 Decreased by -21.77% |
| Feb 25, 26 | 7.70 Increased by +24.39% | 7.10 Increased by +8.45% |
| Oct 29, 25 | 7.16 Increased by +12.05% | 7.32 Decreased by -2.19% |
| Jul 29, 25 | 6.41 Increased by +9.57% | 7.35 Decreased by -12.79% |
| Apr 29, 25 | 6.63 Increased by +7.45% | 6.66 Decreased by -0.46% |
| Feb 19, 25 | 6.19 Increased by +41.97% | 6.27 Decreased by -1.23% |
| Oct 30, 24 | 6.39 Increased by +18.77% | 6.43 Decreased by -0.62% |
| Jul 31, 24 | 5.85 Increased by +11.64% | 6.40 Decreased by -8.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 781.50 M Decreased by -1.62% | 274.90 M Decreased by -14.68% | Increased by +35.18% Decreased by -13.27% |
| Dec 31, 25 | 790.20 M Increased by +7.38% | 364.30 M Increased by +20.91% | Increased by +46.10% Increased by +12.60% |
| Sep 30, 25 | 799.50 M Increased by +6.76% | 338.70 M Increased by +9.58% | Increased by +42.36% Increased by +2.64% |
| Jun 30, 25 | 798.60 M Increased by +11.71% | 309.50 M Increased by +11.29% | Increased by +38.76% Decreased by -0.37% |
| Mar 31, 25 | 794.40 M Increased by +17.22% | 322.20 M Increased by +5.09% | Increased by +40.56% Decreased by -10.35% |
| Dec 31, 24 | 735.90 M Increased by +19.72% | 301.30 M Increased by +38.78% | Increased by +40.94% Increased by +15.93% |
| Sep 30, 24 | 748.90 M Increased by +22.89% | 309.10 M Increased by +15.51% | Increased by +41.27% Decreased by -6.01% |
| Jun 30, 24 | 714.90 M Increased by +19.85% | 278.10 M Increased by +7.29% | Increased by +38.90% Decreased by -10.48% |